Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate
- Indications Meningococcal infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; Pfizer
- 21 Sep 2017 Planned End Date changed from 10 Nov 2017 to 14 Nov 2017.
- 21 Sep 2017 Planned primary completion date changed from 10 Nov 2017 to 14 Nov 2017.
- 18 Apr 2017 Planned End Date changed from 1 Oct 2017 to 10 Nov 2017.